Orion Osake

Orion EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Orion (271560.KS) 18.8.2026 päivämäärällä on 574,52 Mrd. KRW. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 522,85 Mrd. KRW — muutos 9,88 % (korkeampi).

EBITDA

574,52 Mrd.KRW

YoY

9,88%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Orion on 2026 574,52 Mrd. KRW. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Orion oli 2025 522,85 Mrd. KRW. Se laskee 9,88% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Orion Osakeanalyysi

Mitä Orion tekee? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Orion osakkeesta

Yhtiön Orion EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 574,52 Mrd. KRW vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Orion muuttui arvosta 522,85 Mrd. KRW arvoon 574,52 Mrd. KRW, mikä edustaa 9,88 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Orion:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n KRW on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Orion historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Orion

Kaikki tunnusluvut — Orion